Literature DB >> 23370479

Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy.

S Chawla1, J Krejza, A Vossough, Y Zhang, G S Kapoor, S Wang, D M O'Rourke, E R Melhem, H Poptani.   

Abstract

BACKGROUND AND
PURPOSE: Oligodendrogliomas with 1p/19q chromosome LOH are more sensitive to chemoradiation therapy than those with intact alleles. The usefulness of dynamic susceptibility contrast-PWI-guided ¹H-MRS in differentiating these 2 genotypes was tested in this study.
MATERIALS AND METHODS: Forty patients with oligodendrogliomas, 1p/19q LOH (n = 23) and intact alleles (n = 17), underwent MR imaging and 2D-¹H-MRS. ¹H-MRS VOI was overlaid on FLAIR images to encompass the hyperintense abnormality on the largest cross-section of the neoplasm and then overlaid on CBV maps to coregister CBV maps with ¹H-MRS VOI. rCBVmax values were obtained by measuring the CBV from each of the selected ¹H-MRS voxels in the neoplasm and were normalized with respect to contralateral white matter. Metabolite ratios with respect to ipsilateral Cr were computed from the voxel corresponding to the rCBVmax value. Logistic regression and receiver operating characteristic analyses were performed to ascertain the best model to discriminate the 2 genotypes of oligodendrogliomas. Qualitative evaluation of conventional MR imaging characteristics (patterns of tumor border, signal intensity, contrast enhancement, and paramagnetic susceptibility effect) was also performed to distinguish the 2 groups of oligodendrogliomas.
RESULTS: The incorporation of rCBVmax value and metabolite ratios (NAA/Cr, Cho/Cr, Glx/Cr, myo-inositol/Cr, and lipid + lactate/Cr) into the multivariate logistic regression model provided the best discriminatory classification with sensitivity (82.6%), specificity (64.7%), and accuracy (72%) in distinguishing 2 oligodendroglioma genotypes. Oligodendrogliomas with 1p/19q LOH were also more associated with paramagnetic susceptibility effect (P < .05).
CONCLUSIONS: Our preliminary results indicate the potential of combing PWI and ¹H-MRS to distinguish oligodendroglial genotypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23370479      PMCID: PMC8051455          DOI: 10.3174/ajnr.A3384

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  46 in total

1.  Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation.

Authors:  C C Quarles; B D Ward; K M Schmainda
Journal:  Magn Reson Med       Date:  2005-06       Impact factor: 4.668

2.  Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.

Authors:  Michael D Jenkinson; Daniel G du Plessis; Trevor S Smith; Kathy A Joyce; Peter C Warnke; Carol Walker
Journal:  Brain       Date:  2006-05-02       Impact factor: 13.501

3.  Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas.

Authors:  R G Henry; D B Vigneron; N J Fischbein; P E Grant; M R Day; S M Noworolski; J M Star-Lack; L L Wald; W P Dillon; S M Chang; S J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

4.  MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.

Authors:  M D Jenkinson; T S Smith; K Joyce; D Fildes; D G du Plessis; P C Warnke; C Walker
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

5.  Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

Authors:  Fabio M Iwamoto; Linda Nicolardi; Alexis Demopoulos; Violetta Barbashina; Paulo Salazar; Marc Rosenblum; Adília Hormigo
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

6.  Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.

Authors:  Gurpreet S Kapoor; Timothy A Gocke; Sanjeev Chawla; Robert G Whitmore; Ali Nabavizadeh; Jaroslaw Krejza; Joanna Lopinto; Justin Plaum; Eileen Maloney-Wilensky; Harish Poptani; Elias R Melhem; Kevin D Judy; Donald M O'Rourke
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 7.  Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.

Authors:  Martin J van den Bent
Journal:  Semin Oncol       Date:  2003-12       Impact factor: 4.929

8.  Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas.

Authors:  Sanjeev Chawla; Laura Oleaga; Sumei Wang; Jaroslaw Krejza; Ronald L Wolf; John H Woo; Donald M O'Rourke; Kevin D Judy; Michael S Grady; Elias R Melhem; Harish Poptani
Journal:  J Neuroimaging       Date:  2010-01       Impact factor: 2.486

9.  Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study.

Authors:  A Rosemary Tate; Carles Majós; Angel Moreno; Franklyn A Howe; John R Griffiths; Carles Arús
Journal:  Magn Reson Med       Date:  2003-01       Impact factor: 4.668

10.  Correlation of in vitro infiltration with glioma histological type in organotypic brain slices.

Authors:  S Palfi; K R Swanson; S De Boüard; F Chrétien; R Oliveira; R K Gherardi; J M Kros; M Peschanski; C Christov
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more
  34 in total

1.  Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.

Authors:  Anna Latysheva; Kyrre Eeg Emblem; Petter Brandal; Einar Osland Vik-Mo; Jens Pahnke; Kjetil Røysland; John K Hald; Andrés Server
Journal:  Neuroradiology       Date:  2019-02-02       Impact factor: 2.804

Review 2.  Genetics and imaging of oligodendroglial tumors.

Authors:  Jonathan R Ellenbogen; Carol Walker; Michael D Jenkinson
Journal:  CNS Oncol       Date:  2015-10-19

3.  Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.

Authors:  Min Kyoung Lee; Ji Eun Park; Youngheun Jo; Seo Young Park; Sang Joon Kim; Ho Sung Kim
Journal:  Eur Radiol       Date:  2019-08-24       Impact factor: 5.315

4.  Conventional and advanced (DTI/SWI) neuroimaging findings in pediatric oligodendroglioma.

Authors:  Matthias W Wagner; Andrea Poretti; Thierry A G M Huisman; Thangamadhan Bosemani
Journal:  Childs Nerv Syst       Date:  2015-03-27       Impact factor: 1.475

5.  Grading of oligodendroglial tumors of the brain with apparent diffusion coefficient, magnetic resonance spectroscopy, and dynamic susceptibility contrast imaging.

Authors:  Muhammad Atif Naveed; Pradeep Goyal; Ajay Malhotra; Xiang Liu; Sonali Gupta; Manisha Mangla; Rajiv Mangla
Journal:  Neuroradiol J       Date:  2018-02-22

Review 6.  Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy.

Authors:  Ramon Francisco Barajas; Soonmee Cha
Journal:  CNS Oncol       Date:  2014-11

7.  A rare case of oligoastrocytoma with atypical symptoms initially diagnosed as multiple sclerosis: A case report.

Authors:  Jiguo Gao; Yanli Ti; Hongmei Meng; Teng Zhao; Chunkui Zhou; Lijun Zhu; Shaokuan Fang
Journal:  Mol Clin Oncol       Date:  2015-11-25

8.  Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging.

Authors:  Hyun Jung Yoon; Kook Jin Ahn; Song Lee; Jin Hee Jang; Hyun Seok Choi; So Lyung Jung; Bum Soo Kim; Shin Soo Jeun; Yong Kil Hong
Journal:  Neuroradiology       Date:  2017-05-26       Impact factor: 2.804

9.  Lack of choline elevation on proton magnetic resonance spectroscopy in grade I-III gliomas.

Authors:  Sanjeev Chawla; Seung-Cheol Lee; Suyash Mohan; Sumei Wang; MacLean Nasrallah; Arastoo Vossough; Jaroslaw Krejza; Elias R Melhem; S Ali Nabavizadeh
Journal:  Neuroradiol J       Date:  2019-05-03

10.  Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.

Authors:  P P Batchala; T J E Muttikkal; J H Donahue; J T Patrie; D Schiff; C E Fadul; E K Mrachek; M-B Lopes; R Jain; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-01-31       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.